9th European Multidisciplinary Meeting on Urological Cancers (EMUC17)
Multidisciplinary strategies in urogenital cancers

Friday, 17 November

08.15 - 08.20  Welcome and Introduction
Medical oncologist  Thomas Powles, London (GB) - ESMO
Radiation oncologist  Peter Hoskin, Northwood (GB) - ESTRO
Urologist  Hein van Poppel, Leuven (BE) - EAU

08.20 - 10.05  Locally advanced and high risk prostate cancer
Chairs:  Radiologist - Raymond Oyen, Leuven (BE)
Radiation oncologist - Thomas Wiegel, Ulm (DE)
Urologist - Francesco Montorsi, Milan (IT)

08.20 - 09.00  MRI before biopsy for all men?
YES  Urologist - Hashim Ahmed, London (GB)
Radiologist - Harriet Thoeny, Berne (CH)
vs
NO  Radiologist - Olivier Rouvière, Lyon (FR)
Urologist - Jochen Walz, Marseille (FR)

Last judgement:
Urologist - Nicolas Mottet, Saint-Étienne (FR)

09.00 - 09.15  Index lesion in prostate cancer: Myth or reality?
Pathologist - Mark Rubin, New York (US)

09.15 - 09.20  Questions and answers

09.20 - 09.50  Will level 1 evidence influence our practice in focal therapy?
YES  Urologist - Mark Emberton, London (GB)
vs
NO  Radiation oncologist - Alberto Bossi, Villejuif (FR)

Last judgement:
Urologist - Arnauld Villers, Lille (FR)

09.50 - 10.05  Discussion

10.05 - 10.50  The optimal primary treatment of prostate cancer: A focus on the ProtecT study
Chairs:  Radiologist - Raymond Oyen, Leuven (BE)
Radiation oncologist - Thomas Wiegel, Ulm (DE)
Urologist - Francesco Montorsi, Milan (IT)

10.05 - 10.15  ProtecT: What have we learnt?
Radiation oncologist - Freddie Hamdy, Oxford (GB)
Would modern staging change the results?
Urologist - Silvan Boxler, Berne (CH)

The statistician point of view
Biostatistician - Mahesh Parmar, London (GB)

Discussion

Coffee break and poster viewing

Immunotherapy in urological cancers
Chairs: Medical oncologist - Gerhardt Attard, Surrey (GB)
Urologist - Alexander Govorov, Moscow (RU)
Pathologist - Rodolfo Montironi, Ancona (IT)

Biological basics of immune therapy
Immunologist - Elfriede Nosssner, Munich (DE)

Prostate cancer
Medical oncologist - Charles Drake, Baltimore (US)

Bladder cancer
Medical oncologist - Andrea Necchi, Milan (IT)

Kidney cancer
Medical oncologist - Thomas Powles, London (GB)

Discussion

Summary of EPCCCM
Urologist – Manfred Wirth, Dresden (DE)

Lunch break and poster viewing

Industry session

Educational session on testis cancer: Clinical case discussion
Chairs: Clinical oncologist - Jan Oldenburg, Oslo (NO)
Radiation oncologist - Peter Hoskin, Northwood (GB)
Urologist - Fred Witjes, Nijmegen (NL)
Pathologist - Michelangelo Fiorentino, Bologna (IT)

Management of stage 1
Urologist - Peter Albers, Düsseldorf (DE)

Management of metastatic disease
Medical oncologist - Karim Fizazi, Villejuif (FR)

Case discussion “stage I Seminoma” Case presentation
Urologist - Peter Albers, Düsseldorf (DE)
Case discussion “Residual disease”
Urologist - Peter Albers, Düsseldorf (DE)
Medical oncologist - Karim Fizazi, Villejuif (FR)
Radiation oncologist - Gert De Meerleer, Ghent (BE)

15:15-15:30 Best of journal session: Radiotherapy
Chairs: Radiation oncologist - Bradley Pieters, Amsterdam (NL)
       Radiation oncologist - Pirus Ghadjar, Berlin (DE)

15:30 - 16:00 Coffee break and poster viewing

16:00 - 17:45 Educational session on bladder cancer: Clinical case discussion
Chairs: Radiotherapist - Anne Kiltie, Oxford (GB)
       Urologist - George Thalmann, Berne (CH)
       Pathologist - Antonio Lopez-Beltran, Lisbon (PT)
       Medical oncologist - Maria De Santis, Coventry (GB)

16.00 - 16.20 Bladder preservation: How and for whom?
Radiation oncologist - Nicholas James, Birmingham (GB)

16.20 - 16.35 Lymph node dissection: How high is enough?
Urologist – Stephen Boorjian, Rochester (US)

16.35 - 16.50 Molecular sub-types and implications for prognosis and therapy
Urologist - Roland Seiler, Berne (CH)

16.50 - 17.45 Case discussion by the panel and interaction with audience (1 case with cN1, 1 case on fit elderly patient, 1 case on neuroendocrine differentiation)
Radiation oncologist - Nicholas James, Birmingham (GB)
Urologist - Stephen Boorjian, Rochester (US)
Urologist - Roland Seiler, Berne (CH)

17.45 - 18.45 Industry session

Saturday, 18 November

08.15 - 08.30 Announcement 3 best unmoderated posters
Chairs: Clinical oncologist - Jan Oldenburg, Oslo (NO)
       Urologist - Michiel Sedelaar, Nijmegen (NL)

08.30 - 10.15 Oligometastatic kidney cancer
Chairs: Radiation oncologist - Vincent Khoo, London (GB)
       Urologist - Hein Van Poppel, Leuven (BE)
       Medical oncologist - Bernard Escudier, Villejuif (FR)
       Pathologist - Ferran Algaba, Barcelona (ES)
08.30 - 08.45  The optimal timing of cytoreductive nephrectomy
Urologist - Axel Bex, Amsterdam (NL)

08.45 - 09.00  Expanding knowledge of adjuvant therapy
Urologist - Karim Bensalah, Rennes (FR)

09.00 - 09.15  Potential biomarkers for decision making
Urological researcher - Kerstin Junker, Homburg (DE)

09.15 - 09.25  Can local ablation delay the use of systemic therapy for oligometastasis - Radiation therapy
Radiation oncologist - Piet Ost, Ghent (BE)

09.25 - 09.35  Can local ablation delay the use of systemic therapy for oligometastasis - Surgery
Urologist - Susanne Krege, Essen (DE)

09.35 - 10.15  Case discussion by the panel and interaction with audience (we need 1 case with upfront M+ disease, young high risk/M0 patient, patient with progressing disease)
Urologist - Umberto Capitanio, Milan (IT)

10.15 – 10.45  Coffee break and poster viewing

10.45 - 11.25  Oral presentations of the 6 best abstracts
Chairs: Medical oncologist - Susanne Osanto, Leiden (NL)
        Urologist - Hein Van Poppel, Leuven (BE)
        Radiation therapist - Barbara Jerecze-Fossa, Milan (IT)

11.25 - 11.45  Highlights of APCCC2017
Medical oncologist - Silke Gillessen, St. Gallen (CH)

11.45 - 12.15  Is there a shift for selection criteria and definition of reclassification for prostate cancer on active surveillance?
Introduction: Pathologist - Rodolfo Montironi, Ancona (IT)
Pathologist - Jonathan I. Epstein, Baltimore (US)

12.15 - 12.45  Stand-alone session on recent updates/novelties (name TBC)

12.45 - 14.00  Lunch break and poster viewing
13.00 - 14.00  Industry session

14.00 - 16.05  Management of loco/regional recurrences (prostate/penile cancer)
Chairs: Medical oncologist - Silke Gillessen, St. Gallen (CH)
        Urologist - Georg Salomon, Hamburg (DE)
        Radiation therapist - Cesare Cozzarini, Milan (IT)

14.00 - 14.15  MRI/whole body MRI
Radiologist - Frederice Lecouvet, Brussels (BE)

14.15 - 14.35  Use of PET/CT
Nuclear medicine - Stefano Fanti, Bologna (IT)

14.35 - 14.45  Salvage surgery after radiotherapy
Urologist - Steven Joniau, Leuven (BE)
14.45 - 15.00  Salvage treatment after radical prostatectomy  
Radiation oncologist - Pirus Ghadjar, Berlin (DE)

15.00 - 15.15 Management of local recurrences in penile cancer  
Urologist - Chris Protzel, Rostock (DE)

15.15 - 16.05 Case discussion by the panel and interaction with audience (1 case for re-radiotherapy vs salvage RP, 1 case with nodal relapse)  
Urologist - Gianluca Giannarini, Udine (IT)

16.05 - 16.35 Coffee break and poster viewing

16.35 - 16.50 Best of journals: Surgery  
Chairs:  Urologist - Maurizio Brausi, Modena (IT)  
         Urologist - Jochen Walz, Marseille (FR)

16.50 - 17.45 Educational session: Challenging cases in the management of Upper urinary tract TCC  
Chairs : Urologist - Evanguelos Xylinas, Paris (FR)  
         Urologist - Joan Palou, Barcelona (ES)  
         Clinical case discussion (including peri-operative chemo, imaging, pathologist, biopsy)  
         Clinical Oncologist - Ananya Choudhury, Manchester (UK)  
         Urologist - Morgan Roupret, Paris (FR)  
         Pathologist - Sara Falzarano, Cleveland (US)

17.45 - 18.45 Industry session

Sunday, 19 November

08.30 - 08.45 Announcement 3 best unmoderated posters (3x 2 min slide presentation)  
Chairs:  Medical oncologist - Silke Gillessen, St. Gallen (CH)  
         Urologist - Igle-Jan de Jong, Groningen (NL)

08.45 - 09.00 Best of journals: Medical oncology  
Chairs:  Medical oncologist - Cora Sternberg, Rome (IT)  
         Medical oncologist - Andrea Necchi, Milan (IT)

09.00 - 09.15 Drug repurposing opportunities in uro-oncology  
Chairs:  Medical oncologist - Cora Sternberg, Rome (IT)  
         Urologist – Hein van Poppel, Leuven (BE)
         Dr. Director Anticancer fund – Gauthier Bouche, Strombeek-Bever (BE)

09.15 - 11.00 Evolving concepts in metastatic prostate cancer  
Chairs:  Medical oncologist - Cora Sternberg, Rome (IT)  
         Urologist - Jeffrey Karnes, New York (US)  
         Radiation therapist - Thomas Wiegel, Ulm (DE)

09.15 - 09.30 How should we treat our metastatic castrate sensitive patients?  
Medical oncologist - Karim Fizazi, Villejuif (FR)
09.30 - 09.45 Monitoring patients with metastatic disease
Radiologist - Anwar Padhani, Northwood (GB)

09.45 - 10.00 Treatment of the primary in metastatic patients
Urologist - Markus Graefen, Hamburg (DE)

10.00 - 10.15 Molecular radiotherapy
Radiologist - Uwe Haberkorn, Heidelberg (DE)

10.15 - 11.00 Case discussion by the panel and interaction with audience (we need 1 case with oligoM+ then becoming poly-M+, 1 de-novo high volume M+ disease)
Urologist - Simon Brewster, Oxford (GB)

11.00 - 11.30 European Commission lecture
Director General for Health and Food Safety - Xavier Prats Monné, Barcelona (ES)

11.30 - 12.20 Take home messages
11.30 - 11.40 Radiologist - Harriet Thoeny, Bern (CH)
11.40 - 11.50 Urologist - Igle-Jan de Jong, Groningen (NL)
11.50 - 12.00 Medical oncologist - Silke Gillessen, St. Gallen (CH)
12.00 - 12.10 Radiation oncologist - Bradley Pieters, Amsterdam (NL)
12.10 - 12.20 Pathologist - Rodolfo Montironi, Ancona (IT)

12.20 - 12.30 Closing remarks
Medical oncologist Thomas Powles, London (GB) - ESMO
Radiation oncologist Peter Hoskin, Northwood (GB) - ESTRO
Urologist Hein van Poppel, Leuven (BE) - EAU